Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia
A Pilot Study to Evaluate the Therapeutic Effect of Dihydroartemisinin on Female Androgenetic Alopecia
Shanghai Zhongshan Hospital
30 participants
Jun 1, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults. The main question it aims to answer is: • Does DHA increase terminal hair follicles in the vertex area. Researchers will compare oral DHA plus topical minoxidil to topical minoxidil alone in female patients with AGA to see if DHA works to alleviate AGA. Participants will: * Receive oral DHA every day plus topical minoxidil or use topical minoxidil alone for 6 months. * Visit the clinic once every month for checkups and tests.
Eligibility
Inclusion Criteria2
- Clinically diagnosed with androgenetic alopecia (AGA)
- No pregnancy plans within the next 6 months
Exclusion Criteria4
- Patients who received systemic medications for hair loss within the past 2 months
- Use of topical medication for hair loss within the past 2 weeks
- Pregnancy or lactation
- Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DHA 20mg tid po plus daily topical minoxidil 5% for 180 days
Topical minoxidil 5% daily for 180 days
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07012486